Marinus Pharmaceuticals (MRNS) Stock Forecast & Price Target

$0.23 -0.01 (-3.56%)

(As of 12/20/2024 05:31 PM ET)

Marinus Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 11 Analyst Ratings

Sell
0

Hold
8

Buy
3

Based on 11 Wall Street analysts who have issued ratings for Marinus Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 8 have given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for MRNS.

Consensus Price Target

$4.79
1,980.75% Upside

According to the 11 analysts' twelve-month price targets for Marinus Pharmaceuticals, the average price target is $4.79. The highest price target for MRNS is $10.00, while the lowest price target for MRNS is $0.50. The average price target represents a forecasted upside of 1,980.75% from the current price of $0.23.

Get the Latest News and Ratings for MRNS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Marinus Pharmaceuticals and its competitors.

MRNS Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)	8 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	4 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$4.79	$4.79	$9.20	$20.72
Forecasted Upside	1,980.75% Upside	1,444.28% Upside	454.22% Upside	98.49% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

MRNS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Marinus Pharmaceuticals Stock vs. The Competition

Type	Marinus Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.36	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	1,980.75% Upside	25,828.55% Upside	14.54% Upside
News Sentiment Rating	Neutral News See Recent MRNS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/14/2024	Cantor Fitzgerald 4 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$4.00 ➝ $4.00	+1,214.45%
11/14/2024	HC Wainwright 2 of 5 stars	D. Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00	+561.58%
10/25/2024	TD Cowen 5 of 5 stars	J. Thome Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
10/25/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$3.00 ➝ $1.00	+203.02%
10/25/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$5.00 ➝ $0.50	+68.92%
10/24/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
Get the Latest News and Ratings for MRNS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
10/24/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
9/30/2024	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/23/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$6.00	+261.44%
8/14/2024	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Higgins Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/16/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Neutral
1/23/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$27.00 ➝ $23.00	+307.08%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:03 AM ET.

MRNS Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Marinus Pharmaceuticals is $4.79, with a high forecast of $10.00 and a low forecast of $0.50.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 8 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNS, but not buy additional shares or sell existing shares.
: According to analysts, Marinus Pharmaceuticals's stock has a predicted upside of 1,980.75% based on their 12-month stock forecasts.
: Over the previous 90 days, Marinus Pharmaceuticals's stock had 2 upgrades and 1 downgrade by analysts.
: Marinus Pharmaceuticals has been rated by research analysts at Cantor Fitzgerald, EF Hutton Acquisition Co. I, HC Wainwright, Jefferies Financial Group, JMP Securities, Oppenheimer, Royal Bank of Canada, TD Cowen, and Truist Financial in the past 90 days.
: Analysts like Marinus Pharmaceuticals less than other "medical" companies. The consensus rating for Marinus Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NASDAQ:MRNS) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marinus Pharmaceuticals (MRNS) Stock Forecast & Price Target